<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.115316</article-id><article-id pub-id-type="publisher-id">ACM-42463</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210500000_61164851.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  干扰素-α联合达沙替尼治疗慢性粒细胞白血病取得深部分子反应1例并文献复习
  Deep Molecular Response by IFN-α and Dasatinib Combination with Chronic Myeloid Leukemia: Report of One Case and Review of Literature
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>乔</surname><given-names>晗</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>献启</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院血液科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>05</issue><fpage>2199</fpage><lpage>2203</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  酪氨酸激酶抑制剂耐药在慢性粒细胞白血病中具有挑战性。我们在此报告一例慢性粒细胞白血病患者，其在干扰素-α和达沙替尼联合治疗下成功实现了完全遗传学缓解。
   Drug resistance of tyrosine kinase inhibitors is challenging in chronic myeloid leukemia. Here we report a patient with chronic myeloid leukemia who successfully achieved complete genetic remission under the combination of interferon-α and dasatinib.
 
</p></abstract><kwd-group><kwd>干扰素-α，达沙替尼，慢性粒细胞白血病，深部分子反应, Interferon-α</kwd><kwd> Dasatinib</kwd><kwd> Chronic Myeloid Leukemia</kwd><kwd> Deep Molecular Response</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>酪氨酸激酶抑制剂耐药在慢性粒细胞白血病中具有挑战性。我们在此报告一例慢性粒细胞白血病患者，其在干扰素-α和达沙替尼联合治疗下成功实现了完全遗传学缓解。</p></sec><sec id="s2"><title>关键词</title><p>干扰素-α，达沙替尼，慢性粒细胞白血病，深部分子反应</p></sec><sec id="s3"><title>Deep Molecular Response by IFN-α and Dasatinib Combination with Chronic Myeloid Leukemia: Report of One Case and Review of Literature</title><p>Han Qiao, Xianqi Feng<sup>*</sup></p><p>Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/25-1572227x5_hanspub.png" /></p><p>Received: Apr. 17<sup>th</sup>, 2021; accepted: May 2<sup>nd</sup>, 2021; published: May 21<sup>st</sup>, 2021</p><p><img src="//html.hanspub.org/file/25-1572227x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Drug resistance of tyrosine kinase inhibitors is challenging in chronic myeloid leukemia. Here we report a patient with chronic myeloid leukemia who successfully achieved complete genetic remission under the combination of interferon-α and dasatinib.</p><p>Keywords:Interferon-α, Dasatinib, Chronic Myeloid Leukemia, Deep Molecular Response</p><disp-formula id="hanspub.42463-formula21"><graphic xlink:href="//html.hanspub.org/file/25-1572227x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/25-1572227x8_hanspub.png" /> <img src="//html.hanspub.org/file/25-1572227x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>慢性粒细胞白血病(Chronic myeloid leukemia, CML)是一种造血干细胞克隆性骨髓增生性疾病，其特征是9号和22号染色体易位造成BCR-ABL1融合基因的形成，进而编码产生具有致癌活性的酪氨酸激酶 [<xref ref-type="bibr" rid="hanspub.42463-ref1">1</xref>]。在酪氨酸激酶抑制剂(TKI)伊马替尼问世后，慢性期CML患者的预后得到了显著的改善 [<xref ref-type="bibr" rid="hanspub.42463-ref2">2</xref>]。但是部分CML患者在伊马替尼治疗中出现了耐药，只能通过更换为二代TKIs (如达沙替尼、尼罗替尼、博舒替尼)及三代TKIs (如帕纳替尼)或异基因造血干细胞移植(allo-HSCT)来解决。但由于经济等原因，部分患者无法行allo-HSCT及帕纳替尼治疗，因此在现有的条件下寻找新的可行性治疗方法尤为重要。干扰素-α联合达沙替尼治疗慢性粒细胞白血病取得深部分子反应值得临床参考，现报道如下。</p></sec><sec id="s6"><title>2. 临床资料</title><p>患者，男性，65岁，6年余前因发现左上腹肿块2天就诊于当地医院，查腹部超声示脾大，血常规示白细胞200 &#215; 10<sup>9</sup>/L，经骨髓穿刺检查诊断为慢性粒细胞白血病，服用伊马替尼0.4 g qd治疗，期间未复查骨穿。2017-01-18复查血常规示白细胞29.51 &#215; 10<sup>9</sup>/L，骨髓穿刺示：原始细胞占45%，基因：ABL激酶突变，BCR-ABL P210：60.83%，染色体：47，XY，+8，t(8；22) (q34；q11.2)，i(17) (q10) (20)，骨髓活检病理示：慢性粒细胞白血病伴原始细胞增多和纤维化，不除外疾病进展(加速期)。综上考虑CML (急变期)，但患者及家属拒绝化疗，给予调整为达沙替尼140 mg qd治疗。后于2017-08-22至2018-01-04行5疗程去甲基化治疗，具体治疗方案为：地西他滨25 mg d-5，2018-01-05复查骨穿示骨髓象缓解，BCR-ABL P210：23.44%。自2018-02-05起序贯给予第6、7、8、9疗程去甲基化治疗，2018-04-19复查骨穿示骨髓增生低下，BCR-ABL P210：19.83%。因患者P210下降不明显，且持续粒细胞缺乏，于2018-05-20给予半量HA方案，具体：高三尖杉酯碱2 mg，阿糖胞苷100 mg d1-7。2018-07-03复查骨穿示骨髓增生活跃，粒系增生减低；流式：CD34+ CD117dim HLA-DR+ CD38+ CD13+ CD33+异常髓系原始细胞占有核细胞0.59%；基因：BCR-ABL P210：34.74%，染色体：46，XY，t(9；22)(q34；q11.2)；基因重排：TCR γ、TCR β阴性。自2018-08-17起给予调整方案为达沙替尼140mg qd联合干扰素-α 500万单位qd，2019-03-29复查骨穿：基因：BCR-ABL P210：0.66%，染色体：正常，血常规：血红蛋白100 g/L，白细胞3.41 &#215; 10<sup>9</sup>/L，中性粒细胞1.72 &#215; 10<sup>9</sup>/L，血小板165 &#215; 10<sup>9</sup>/L。2019-09-02复查骨穿：BCR-ABL P210：0.3284%，血常规：血红蛋白93 g/L，白细胞3.92 &#215; 10<sup>9</sup>/L，中性粒细胞2.19 &#215; 10<sup>9</sup>/L，血小板225 &#215; 10<sup>9</sup>/L。</p></sec><sec id="s7"><title>3. 讨论</title><p>CML是血液科常见的造血干细胞恶性克隆性疾病，1973年，Janet Rowley博士发现了9号染色体和22号染色体长臂(t(9；22) (q34；q11))之间的相互易位，导致22号染色体缩短，即费城染色体(Ph) [<xref ref-type="bibr" rid="hanspub.42463-ref3">3</xref>]。随着DNA克隆和测序的进展，BCR-ABL转录本被鉴定出来，并被预测编码具有酪氨酸激酶活性的融合蛋白 [<xref ref-type="bibr" rid="hanspub.42463-ref4">4</xref>]，后有研究将BCR-ABL转基因引入小鼠体内，并最终将融合基因与白血病的发生联系起来 [<xref ref-type="bibr" rid="hanspub.42463-ref5">5</xref>]。CML主要分为慢性期(CP)、加速期(AP)、急变期(BC)，若不经特殊治疗，多数患者数年内即进入BC终末期，极大的降低了预期寿命。由于各分期之间的生活质量差异极大，且疾病本质存在差异，目前CML的治疗的最终目的是预防疾病进展。</p><p>在早期，CML的治疗主要以化疗为主，如白消安、羟基脲、阿糖胞苷，但它们的治疗作用主要是基于细胞周期对外周血白细胞的杀伤，对控制疾病的进展作用微乎其微。后来干扰素-α被证实具有抗髓系恶性肿瘤的活性，对1500多名随机患者的mate分析显示，使用干扰素α的患者5年存活率为50%~59%，较接受白消安或羟基脲的患者明显升高 [<xref ref-type="bibr" rid="hanspub.42463-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.42463-ref7">7</xref>]，随后干扰素α被推广为一线用药，但仍不可避免的缩短患者的寿命。第一代靶向酪氨酸激酶抑制剂(TKI)的药物伊马替尼在2001年被FDA和EMA批准为CML的一线治疗，它的出现使CML患者获得更好的耐受性，并诱导更高的CHR和CCyR率。在伊马替尼之后，第二代和第三代TKIs被开发出来，最近的研究表明，达沙替尼和尼罗替尼在CCyR、MMR和预防进展到加速期和爆发期方面均优于标准剂量伊马替尼 [<xref ref-type="bibr" rid="hanspub.42463-ref8">8</xref>]，目前的治疗指南还建议对伊马替尼治疗不耐受或耐药的患者可更换为尼罗替尼或达沙替尼 [<xref ref-type="bibr" rid="hanspub.42463-ref9">9</xref>]。异基因造血干细胞移植是目前治愈白血病的唯一方法，但在CML中由于其生存期较TKIs治疗无明显获益，且往往费用及治疗代价较大，目前不作为首选治疗方案，但对于多种TKI治疗失败及耐药的患者可作为治疗的选择。</p><p>目前伊马替尼仍是CML的一线用药，尤其是随着TKIs的发展，大多数患者的疾病进程控制良好，其寿命甚至延长至接近正常，尽管取得了这一显著成就，TKIs耐药这一挑战仍然存在于CML的治疗中。这是由于随着时间的推移，CML造血干细胞的克隆进化、基因组的不稳定性、Ph(+)肿瘤祖细胞的增殖/抗凋亡、BCR-ABL酪氨酸激酶增加的氧化应激和突变表型的改变、额外的突变事件的获得使CML的生物学和临床表现复杂化 [<xref ref-type="bibr" rid="hanspub.42463-ref10">10</xref>]。其中BCR-ABL激酶结构域内的点突变是伊马替尼耐药最常见的原因，最近对伊马替尼治疗耐药患者的分析显示M244V、G250E、Y253F/H、E255K/V、T315I、M351T和F359V占所有耐药相关突变的85% [<xref ref-type="bibr" rid="hanspub.42463-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.42463-ref12">12</xref>]。在治疗失败的情况下，慢性粒细胞白血病治疗指南指出，继续目前剂量的伊马替尼治疗不再是合适的治疗策略，可通过增加剂量或升级为二代、三代TKIs继续慢性期的治疗 [<xref ref-type="bibr" rid="hanspub.42463-ref13">13</xref>]。</p><p>本例病人，既往应用了3年余标准剂量伊马替尼治疗后疾病进入了加速期，考虑因伊马替尼耐药所致，给予更换为二代TKIs达沙替尼继续治疗，并给予多疗程去甲基化治疗控制疾病的进程，但患者在去甲基化治疗后出现了较长时间的骨髓抑制，且分子学缓解不明显。由于目前三代TKIs费用昂贵，且患者经济条件不足以进行allo-HSCT，在此基础上我们给予调整治疗方案为达沙替尼140 mg qd联合干扰素-α 500万单位qd。截止到目前患者已取得CCyR、MMR及CHR，且治疗过程中的副作用可耐受。此外，有另外的案例报道伴有T315I和E255V BCR-ABL1突变的1例患者在达沙替尼和IFN-α联合治疗下成功实现了深层分子应答 [<xref ref-type="bibr" rid="hanspub.42463-ref14">14</xref>]。</p><p>在TKIs出现后干扰素-α不再是CML的一线用药，但近年有临床试验表明，干扰素-α联合TKIs较TKIs单药治疗可获得更高的CCyR、MMR及CHR，在H Hjorth-Hansen的临床试验表明达沙替尼和干扰素-α对慢性粒细胞白血病具有抗白血病和免疫刺激作用，并能诱导深度反应 [<xref ref-type="bibr" rid="hanspub.42463-ref15">15</xref>]。此外有研究表明，Ph + CML白血病干细胞的存活并不依赖于BCR-ABL的活性，因为它们大多存在于骨髓中，而干扰素α可促进正常静止造血干细胞循环，对休眠白血病干细胞(LSCs)也有类似的作用机制，使其离开髓内进入循环，从而使LSCs暴露于TKIs和化疗药物的作用下 [<xref ref-type="bibr" rid="hanspub.42463-ref16">16</xref>]。同时干扰素-α可通过对CML祖细胞的直接抗增殖作用发挥其抗白血病作用，是目前唯一可诱导CCyR的药物 [<xref ref-type="bibr" rid="hanspub.42463-ref17">17</xref>]。</p></sec><sec id="s8"><title>4. 结论</title><p>综上所述，TKIs的发展极大的改善了CML患者的预后，提高了预期寿命，但治疗过程中的耐药仍是巨大的挑战，通常需增加剂量或更换为二代、三代TKIs。然而，由于患者身体和经济条件的差异，并非每个患者都能从新的TKIs中获益。在这种情况下，干扰素-α联合达沙替尼治疗后获得了深层的分子反应，表明了新的治疗途径，展现了联合治疗策略在CML中的潜力。</p></sec><sec id="s9"><title>声明</title><p>该病例报道获得病人的知情同意。</p></sec><sec id="s10"><title>文章引用</title><p>乔 晗,冯献启. 干扰素-α联合达沙替尼治疗慢性粒细胞白血病取得深部分子反应1例并文献复习Deep Molecular Response by IFN-α and Dasatinib Combination with Chronic Myeloid Leukemia: Report of One Case and Review of Literature[J]. 临床医学进展, 2021, 11(05): 2199-2203. https://doi.org/10.12677/ACM.2021.115316</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42463-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Jabbour, E. and Kantarjian, H. (2016) Chronic Myeloid Leukemia: 2016 Update on Diagnosis, Therapy, and Monitoring. American Journal of Hematology, 91, 252-265. &lt;br&gt;https://doi.org/10.1002/ajh.24275</mixed-citation></ref><ref id="hanspub.42463-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Druker, B.J., Guilhot, F., O’Brien, S.G., et al. (2006) Five-Year Follow-Up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. The New England Journal of Medicine, 355, 2408-2417. &lt;br&gt;https://doi.org/10.1056/NEJMoa062867</mixed-citation></ref><ref id="hanspub.42463-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Rowley, J.D. (1973) Letter: A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining. Nature, 243, 290-293. &lt;br&gt;https://doi.org/10.1038/243290a0</mixed-citation></ref><ref id="hanspub.42463-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Shtivelman, E., Lifshitz, B., Gale, R.P., et al. (1985) Fused Transcript of abl and bcr Genes in Chronic Myelogenous Leukaemia. Nature, 315, 550-554. &lt;br&gt;https://doi.org/10.1038/315550a0</mixed-citation></ref><ref id="hanspub.42463-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Daley, G.Q., Van Etten, R.A. and Baltimore, D. (1990) Induction of Chronic Myelogenous Leukemia in Mice by the P210bcr/abl Gene of the Philadelphia Chromosome. Science, 247, 824-830. &lt;br&gt;https://doi.org/10.1126/science.2406902</mixed-citation></ref><ref id="hanspub.42463-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tura, S., Baccarani, M., Zuffa, E., et al. (1994) Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia. The New England Journal of Medicine, 330, 820-825.  
&lt;br&gt;https://doi.org/10.1056/NEJM199403243301204</mixed-citation></ref><ref id="hanspub.42463-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">(1997) Interferon Alfa versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-Analysis of Seven Randomized Trials: Chronic Myeloid Leukemia Trialists’ Collaborative Group. Journal of the National Cancer Institute, 89, 1616- 1620. &lt;br&gt;https://doi.org/10.1093/jnci/89.21.1616</mixed-citation></ref><ref id="hanspub.42463-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kantarjian, H., Shah, N.P., Hochhaus, A., et al. (2010) Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. The New England Journal of Medicine, 362, 2260-2270.  
&lt;br&gt;https://doi.org/10.1056/NEJMoa1002315</mixed-citation></ref><ref id="hanspub.42463-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">O’Brien, S., Berman, E., Borghaei, H., et al. (2009) NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network, 7, 984-1023.  
&lt;br&gt;https://doi.org/10.6004/jnccn.2009.0065</mixed-citation></ref><ref id="hanspub.42463-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Haznedaroglu, I.C. (2015) Drug Therapy in the Progressed CML Patient with Multi-TKI Failure. Mediterranean Journal of Hematology and Infectious Diseases, 7, e2015014. &lt;br&gt;https://doi.org/10.4084/mjhid.2015.014</mixed-citation></ref><ref id="hanspub.42463-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ernst, T. and Hochhaus, A. (2012) Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated with Disease Progression. Seminars in Oncology, 39, 58-66.  
&lt;br&gt;https://doi.org/10.1053/j.seminoncol.2011.11.002</mixed-citation></ref><ref id="hanspub.42463-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kim, T.D., Türkmen, S., Schwarz, M., et al. (2010) Impact of Additional Chromosomal Aberrations and BCR-ABL Kinase Domain Mutations on the Response to Nilotinib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. Haematologica, 95, 582-588. &lt;br&gt;https://doi.org/10.3324/haematol.2009.014712</mixed-citation></ref><ref id="hanspub.42463-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Baccarani, M., Cortes, J., Pane, F., et al. (2009) Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European Leukemia Net. Journal of Clinical Oncology, 27, 6041-6051.  
&lt;br&gt;https://doi.org/10.1200/JCO.2009.25.0779</mixed-citation></ref><ref id="hanspub.42463-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, L., Shi, H., Jiang, S., et al. (2016) Deep Molecular Response by IFN-α and Dasatinib Combination in a Patient with T315I-Mutated Chronic Myeloid Leukemia. Pharmacogenomics, 17, 1159-1163.  
&lt;br&gt;https://doi.org/10.2217/pgs-2016-0049</mixed-citation></ref><ref id="hanspub.42463-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Hjorth-Hansen, H., Stentoft, J., Richter, J., et al. (2016) Safety and Efficacy of the Combination of Pegylated Interferon-α2b and Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients. Leukemia, 30, 1853- 1860. &lt;br&gt;https://doi.org/10.1038/leu.2016.121</mixed-citation></ref><ref id="hanspub.42463-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Essers, M.A., Offner, S., Blanco-Bose, W.E., et al. (2009) IFNalpha Activates Dormant Haematopoietic Stem Cells in Vivo. Nature, 458, 904-908. &lt;br&gt;https://doi.org/10.1038/nature07815</mixed-citation></ref><ref id="hanspub.42463-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Cornelissen, J.J., Ploemacher, R.E., Wognum, B.W., et al. (1998) An in Vitro Model for Cytogenetic Conversion in CML. Interferon-Alpha Preferentially Inhibits the Outgrowth of Malignant Stem Cells Preserved in Long-Term Culture. Journal of Clinical Investigation, 102, 976-983. &lt;br&gt;https://doi.org/10.1172/JCI2366</mixed-citation></ref></ref-list></back></article>